Why Men Snore. And Why It Is Not Just a Nuisance.

Most men who snore have been told to roll over, sleep on their side, or lose weight. Most of them do none of these things and continue snoring, and at some point the topic gets dropped. What does not get dropped is the underlying physiology, which continues operating every night regardless of whether anyone is paying attention to it.

The Mechanism

Snoring is the acoustic signature of a narrowed upper airway. During sleep, the muscles that hold the pharyngeal walls apart relax. If the airway is narrow enough, airflow accelerates through the constriction, and the soft tissues, specifically the soft palate, uvula, and lateral pharyngeal walls, vibrate at the frequency most bed partners know well. The sound itself is mechanically trivial. What it signals is not.

Men have anatomically larger pharyngeal airways than women, which sounds protective. It is not, because men also have greater upper airway collapsibility, driven by differences in airway muscle fiber composition and fat distribution. The Wisconsin Sleep Cohort Study, a landmark prospective study of a community-based sample, established that approximately 24% of middle-aged men had an apnea-hypopnea index of 5 or above, compared with 9% of women in the same age range (Young et al., NEJM, 1993). That 2 to 3 times higher prevalence in men at equivalent ages and body compositions is not explained by anatomy alone: male sex hormones appear to independently reduce upper airway muscle tone, and the distribution of fat around the pharynx differs by sex in ways that compound collapsibility.

Central and pharyngeal fat deposition narrows the airway mechanically. As a man’s neck circumference increases, the soft tissue load on the airway walls increases proportionally, and the effort required to keep the airway patent during sleep rises with it. This is why neck circumference above 17 inches is a recognized clinical risk factor, not just a rough correlation. Weight loss of even 10% of body weight has been shown to reduce apnea severity meaningfully, with some studies reporting AHI reductions of 26% or more from modest weight loss alone (Johansson et al., BMJ 2009).

Sleeping position compounds everything. In positional obstructive sleep apnea, which represents roughly 56% of all OSA cases in population studies, apnea events are at least twice as frequent in the supine position compared to lateral sleep. Gravity pulls the tongue and soft palate posteriorly when a man lies on his back, further narrowing an already compromised airway. Alcohol eliminates the residual protective reflexes: it selectively relaxes the genioglossus muscle, which normally contracts to protect airway patency, and the result is a measurable increase in upper airway collapsibility for 4 to 5 hours after consumption.

The spectrum from snoring to apnea has three distinct zones. Primary snoring: vibration of upper airway tissues without significant oxygen desaturation or cortical arousal. Clinically benign in isolation, though it is not a permanent category, since primary snoring progresses to obstructive sleep apnea in a meaningful proportion of men over time. Upper airway resistance syndrome: increased airway resistance that produces subtle arousals and sleep fragmentation without meeting the event-frequency threshold for apnea. Produces non-restorative sleep and daytime sleepiness. Frequently missed because standard screening focuses on apnea events. Obstructive sleep apnea: complete or partial airway collapse producing apnea or hypopnea events with oxygen desaturation, followed by cortical arousal. Classified by apnea-hypopnea index per hour: mild 5 to 14, moderate 15 to 29, severe 30 and above.

What the Evidence Shows

The Sleep Heart Health Study, a multi-center prospective cohort of over 6,000 adults with objective sleep measurements, remains the foundational cardiovascular evidence base. Published findings from this cohort (doi.org/10.1164/ajrccm.163.1.2001008) demonstrated that severe obstructive sleep apnea independently predicts cardiovascular disease after controlling for established traditional risk factors including age, BMI, smoking, and hypertension. The odds ratio for cardiovascular disease in men with an AHI above 30 was approximately 1.42 compared to men with no sleep-disordered breathing, and this was after the statistical removal of confounders that themselves are partly driven by sleep apnea.

The hypertension connection is the finding with the most direct clinical consequence. The Wisconsin Sleep Cohort showed an odds ratio of approximately 1.37 for hypertension in men with mild sleep apnea (AHI 5 to 14) and approximately 2.9 in men with moderate to severe apnea (AHI above 15), after controlling for BMI, age, and sex. The mechanism is not subtle: each apnea event produces a sympathetic surge that transiently raises blood pressure by 20 to 40 mmHg. In a man with 30 apnea events per hour sleeping 7 hours, that is more than 200 discrete blood pressure spikes per night. The sympathetic nervous system does not fully recover between events; over months and years, the baseline shifts upward permanently.

Atrial fibrillation warrants specific mention. Several large registries have found that patients with OSA have significantly higher rates of AF recurrence after cardioversion or ablation compared to those without OSA. A 2014 analysis published in the Journal of the American College of Cardiology found that untreated OSA conferred a 2-fold increased risk of AF recurrence after catheter ablation. In a man with AF and a history of snoring, this is not a coincidental overlap; it is likely a mechanistic relationship mediated by left atrial enlargement from recurrent nocturnal pressure loading.

The testosterone connection is underappreciated and clinically relevant for men. OSA suppresses endogenous testosterone through two routes: first, testosterone release is tightly coupled to slow-wave sleep, which OSA fragments; second, intermittent nocturnal hypoxia directly suppresses Leydig cell function. Studies of men with moderate to severe OSA show mean morning testosterone levels that are measurably lower than those of age-matched controls without OSA. Treating OSA with CPAP has been shown in randomized trials to partially restore nocturnal testosterone production, an effect that does not require any hormonal supplementation.

CPAP adherence and cardiovascular outcomes data require honest framing. 4 / Promising The SAVE trial (McEvoy et al., NEJM, 2016), a large randomized trial of CPAP versus usual care in patients with moderate to severe OSA and established cardiovascular disease, did not find a significant reduction in major cardiovascular events with CPAP. This was a meaningful negative finding and deserves acknowledgment. The most plausible explanation is that average CPAP adherence in the trial was only 3.3 hours per night, well below the 6 to 7 hours considered necessary for adequate treatment. Observational studies of patients with objectively documented good CPAP adherence show cardiovascular risk profiles closer to those of patients without OSA, though observational data cannot establish causation. The practical inference: CPAP prescribed but used for 2 hours a night is not the same as CPAP used for 7 hours a night.

Screening tools exist and perform reasonably well in practice. The STOP-BANG questionnaire, validated in multiple surgical and general populations, uses 8 binary items: Snoring (loud), Tiredness, Observed apnea, blood Pressure, BMI above 35, Age above 50, Neck circumference above 40 cm, and Gender (male). A score of 3 or above carries a sensitivity of approximately 84% for moderate to severe OSA in general clinic populations. Scores of 5 to 8 carry a positive predictive value above 75% for severe OSA. This is a screening tool, not a diagnostic test, and a low STOP-BANG score in a man with witnessed apneas and resistant hypertension should not override clinical judgment. The Epworth Sleepiness Scale (ESS) measures subjective daytime sleepiness across 8 common situations. A score above 10 out of 24 is generally considered excessive. The ESS captures a different dimension from STOP-BANG: a man with severe OSA may have normalized his fatigue so thoroughly that he scores low on the ESS while still carrying significant cardiovascular risk from nocturnal events.

Home sleep testing versus in-lab polysomnography: home sleep tests measure airflow, respiratory effort, and oxygen saturation and are appropriate for patients with high pretest probability and no significant comorbidities. They tend to underestimate AHI slightly because they cannot capture arousals that do not produce desaturation. In-lab polysomnography remains the reference standard, captures full sleep staging, and is preferred for patients with suspected comorbid conditions such as periodic limb movement disorder, central sleep apnea, or complex sleep architecture disruption. For the typical middle-aged man with loud snoring, witnessed apneas, and either hypertension or daytime sleepiness, a home sleep test is a clinically defensible and far more accessible first step.

CPAP Alternatives: What the Evidence Shows When CPAP Is Not the Right Fit

CPAP has a well-documented adherence problem. Studies using objective device-download data consistently find that 30 to 50 percent of patients prescribed CPAP use it for fewer than 4 hours per night at one year, with many discontinuing entirely within six months. The cardiovascular benefit data for CPAP come from patients using it adequately; a device that sits unused on the nightstand does not reduce sympathetic tone, nocturnal blood pressure surges, or atrial fibrillation risk. For the substantial proportion of men who cannot or will not tolerate CPAP, several alternatives have evidence support.

Mandibular advancement devices (MADs), also called oral appliances, reposition the lower jaw anteriorly during sleep, enlarging the posterior pharyngeal space and reducing airway collapsibility. Compliance rates of 80 to 90 percent at one year are consistently higher than CPAP rates in comparative studies. A systematic review by Ramar and colleagues in the Journal of Clinical Sleep Medicine (2015) found that MADs reduced AHI by an average of 13.6 events per hour, compared with 16.5 events per hour for CPAP, confirming that CPAP provides greater absolute AHI reduction. However, when compliance differences are accounted for, population-level blood pressure reduction from MAD therapy approaches that of CPAP in men who use the device for the full sleep period. Marklund and colleagues published comparative blood pressure data supporting this finding: the effective therapeutic dose, integrated over hours worn, may favor MADs when CPAP compliance is consistently poor. MADs are most effective in mild to moderate OSA and in men with positional predominance; they are less effective in severe OSA with very high AHI. They require fitting by a dentist or oral appliance specialist with sleep medicine training.

Positional therapy addresses the mechanism that approximately 56 percent of OSA cases share: predominance of apnea events in the supine position. Positional OSA, defined as an AHI at least twice as high supine compared to lateral sleep, can be managed effectively in many patients by preventing supine sleep. Commercial positional devices, including vibrating sensors worn on the back of the neck that respond when the wearer is supine, have reduced AHI by 50 to 70 percent in randomized trials of patients with positional OSA. For men with mild to moderate positional OSA who cannot tolerate CPAP, positional therapy has a documented physiological mechanism and reasonable trial evidence.

Hypoglossal nerve stimulation (HNS) is an implantable neurostimulation approach for patients with moderate to severe OSA who have failed CPAP. The Inspire device, FDA-approved in 2014, delivers synchronized electrical stimulation to the hypoglossal nerve, causing tongue protrusion and upper airway opening with each inspiration during sleep. The STAR trial, published by Strollo and colleagues in the New England Journal of Medicine in 2014, enrolled 126 patients with AHI between 20 and 65 events per hour who were unable to tolerate CPAP and found a median AHI reduction from 29.3 to 9.0 events per hour after 12 months. Responder rates, defined as achieving AHI below 15 with at least 50 percent reduction, were approximately 66 percent. Candidates require drug-induced sleep endoscopy to confirm anatomical suitability, specifically excluding complete concentric palatal collapse. For appropriately selected patients with documented CPAP failure, HNS offers AHI reduction data that exceeds what inadequate CPAP use produces.

What to Do This Week

1. Ask your bed partner two specific questions tonight: “Do I snore regularly?” and “Have you ever seen me stop breathing?” Their answers carry more diagnostic weight than your own recollection, because apnea events do not produce conscious memories. If the answer to the second question is yes, that is a witnessed apnea and it meets the threshold for sleep study referral.

2. Complete the STOP-BANG questionnaire honestly. It takes two minutes. A score of 3 or above in a man with habitual snoring justifies requesting a sleep study evaluation from your primary care physician. The test itself, particularly a home sleep test, is straightforward: you wear a small device on your wrist and a sensor on your finger for one night.

3. If your blood pressure has not responded adequately to one or more medications, tell your doctor you want a sleep study before adding another agent. Resistant hypertension and habitual snoring together constitute a clinical indication for sleep apnea evaluation. This is not a fringe recommendation; it appears in cardiology and hypertension guidelines.

4. If you have been told you have atrial fibrillation, or if you have had a cardioversion or ablation, and you snore regularly, speak to your cardiologist specifically about sleep apnea evaluation. AF recurrence rates after ablation are measurably worse in patients with untreated OSA.

5. If you are given a CPAP prescription, use it for the full sleep period. The cardiovascular benefit data, what exists of it, comes from patients who used CPAP for 6 to 7 hours per night. Using it for 2 to 3 hours before removing it in the early morning misses the late-night REM-predominant sleep period, which is when apnea events tend to be most frequent and oxygen desaturation most severe.

The man who dismisses snoring as a nuisance is making a bet that his airway is closing and reopening without consequence. That bet has a reasonable chance of being correct for years. The problem is that the cardiovascular mechanisms, specifically the sympathetic overdrive, the nocturnal blood pressure surges, and the chronic intermittent hypoxia, accumulate silently on the same timeline as atherosclerosis. By the time the consequence is visible on an ECG or a blood pressure cuff that no longer responds to a third medication, the process has been running for a decade. A one-night sleep test is a low-cost way to find out which side of that bet you are on.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.